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Background: Granulocyte transfusions have recently gained popularity for
the treatment of severe infections in neutropenic patients which do not
respond to conventional antimicrobial therapies and recombinant growth
factors. We conducted the present study to determine the clinical course of
patients with neutropenia related infection receiving granulocyte trans-
fusions in our center and to assess its efﬁcacy in resolution of infections.
Methods: Retrospective analysis of all pediatric patients up to 18 years of
age with neutropenia and infection receiving granulocyte transfusions in
our hospital between January 2015 and July 2016.
Results: Twenty one pediatric patients with severe neutropenia related
infections unresponsive to appropriate antimicrobial agents were included
in the study. They received a total of 57 granulocyte transfusions. The study
population comprised of 10 females (47.6%) and 11 males (52.4%). Median
age of the study population was 9 yrs (5 months-16 years). 13 patients
suffering from nonmalignant hematological diseases and 8 patients with
malignant diseases were included in the study population. Voluntary
healthy donors were used after granulocyte mobilization using gran-
ulocyte colony- stimulating factor (G-CSF) and dexamethasone. The me-
dian donor WBC count before leukapheresis was 31.9  109 /L and the
mean donor granulocyte yield was 8.9  1010 /L. Seven patients had
localized infection while 14 had sepsis. Causative organisms could be
isolated in 16 cases out of which gram negative bacillus was isolated in 15
(93.75%). Median duration of neutropenia, antimicrobial therapy and G-
CSF administration before granulocyte transfusion was 11 days (range 2-
34), 10 days (range 3-20) and 9 days (range 2-20) respectively. Patients
received amean of 2.85 (range 1-8) granulocyte transfusions andmean cell
dose of 2.7  1010 granulocytes. Ten of the total twenty one patients
included had a favorable response and recovered from the infection.
Granulocyte transfusions were generally well tolerated inmost of the cases
except for one episode of transfusion associated acute lung injury.
Conclusion: Granulocyte transfusions seem to be a clinically useful and
generally safe adjunct in management of severe neutropenia related
infections.
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BLOOD AND BLOOD PRODUCTS TRANSFUSION AUDIT: CURRENT
PRACTICES AND LACUNAE IN BLOOD AND BLOOD PRODUCT
TRANSFUSION AMONG HOSPITALIZED CHILDREN
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Transfusion audits are most effective tools to detect inappropriate blood
product transfusion practices and suggest remedial measures to ensure
safe and effective use of this precious product in health-care.
Objectives: Present study was designed to assess current practices
regarding blood product transfusions in childrenwith special emphasis on
the appropriateness of these transfusions.
Materials & Method: Present study was a prospective study conducted
over a period of 22 months from January 2013 to October 2014. Each
episode of transfusion was analyzed and divided into appropriate and
inappropriate according to the type of blood component, the clinical and
hematological indication. Data was reviewed according to British Com-
mittee for Standards in Hematology and American Association of Blood
Bank guidelines.Results: In this study, a total 741 transfusions were used in 327 cases,
including 449 packed red blood cells (60.6%), 148 Fresh frozen plasma
(20.0%), 140 (18.9%) platelets and 4 (0.5%) whole blood transfusions.
Appropriate usage of blood and blood products was 70.5%. Most inap-
propriately used was FFP (39.2% of FFP transfusions), followed by Packed
RBCs (28.7%) and Platelets (22.9%). Packed RBCs transfusions were used
most commonly for sepsis with/without DIC (25.2%), followed by nutri-
tional anemia (20.7%) Packed RBC transfusions were used most inappro-
priately for nutritional anemia (49.5%) and sepsis (46.9%). FFP transfusions
were used maximally for the indication of sepsis with/without DIC (43.2%),
followed by perioperative indications (21.6%). FFP transfusions were most
inappropriate for Dengue (68.8%) and perioperative indications (53.1%).
Platelet transfusions were most commonly used for Aplastic anemia (45%)
followed by sepsis (24.3%) Platelet transfusions weremost inappropriate in
Dengue cases (85%) and Idiopathic thrombocytopenic purpura (50%).
Conclusion: Present study concludes that in the study population, about
one-third of all blood component transfusions used in study center are
inappropriate. This study suggests establishment of set protocols for
requisition of blood component transfusions in the study set-up to mini-
mize irrational and unsafe use of these products.
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FUNGAL BRAIN ABSCESS IN HAEMATOLOGICAL MALIGNANCY: IS GOOD
OUTCOME POSSIBLE?
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Institute of Medical Education and Research, Chandigarh, India
Introduction: Incidence of invasive fungal infections in children with
hematological malignancies is increasing. We present clinical features and
outcome of children with fungal brain abscess in acute lymphoblastic
leukemia (ALL), an entity which traditionally has dismal outcomes.
Methods: Eighteen months data is presented. Total 160 new ALL patients
were recruited. Thirteen developed proven fungal infection. Details of
children with fungal CNS infection were retrieved and analyzed.
Results: Five children had fungal brain abscesses. B-cell ALL:T-cell was 4:1.
Three childrenwere standard risk, 2 intermediate risk. All were on intense
chemotherapy including steroids; 4 induction, 1 intensiﬁcation. Clinical
presentation: Prolonged neutropenia: 100%; fever: 100%; altered senso-
rium/seizures seen in 80% (4/5). Duration of neutropenia: 16 days (14-23).
Primary focus was lung in 4, ear in 1. Brain abscess was single in 2, multiple
in 3 children. Meningitis was present in 2. All children underwent surgery
(burr-hole drainage:4, excision:1). Culture/PCR proven fungus was seen in
all: Aspergillus in 4; Mucor:1. Elevated serum galactomannan seen in 66%.
Combination antifungals were given for aspergillus: Amptotericin (plain/
liposomal)& voriconazole for 10 days, followed by voriconazole alone for 6
months. Single mucor patient received amphotericin for 12 months.
Overall survival at 10 months: 80%; event free survival: 40% (events-
death:1, defaulter:1, cortical blindness:1). Three children are continuing
chemotherapy.
Conclusion: Mortality rate in fungal brain infections in children is re-
ported to be 65%. Better outcomes in our patients can be attributed to
multimodality therapy and early initiation of antifungal therapy along
with judicious management of chemotherapy.
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